文献速递妇科产科

绝经后女性激素替代治疗与黑色素瘤风险

Hormone replacement therapy and the risk of melanoma in post-menopausal women.
PubMed 文献 · Hum Reprod · 2019-01-01

该研究基于丹麦全国登记数据,开展病例对照研究和回顾性队列研究,探讨绝经后女性激素替代治疗(HRT)与黑色素瘤风险及预后结局的关联。队列分析未发现HRT使用与黑色素瘤生存结局相关。

要点

  • 高强度HRT使用与黑色素瘤风险相关(OR 1.21,95%CI 1.13-1.29),但无剂量反应关系。
  • 近期高剂量使用、局部病变和阴道内雌激素治疗的风险关联更明显。
  • HRT使用与继发黑色素瘤风险及全因死亡率无显著关联。

核心结论

  • HRT使用与黑色素瘤风险存在关联证据,但缺乏剂量反应关系及近期使用、局部病变和阴道内雌激素的关联模式,提示为非因果关联。
  • HRT使用与黑色素瘤生存结局无关联。

研究设计与样本

  • 全国性人群基础病例对照研究及回顾性队列研究,利用丹麦医疗登记数据。
  • 队列研究纳入6575名2000-2013年诊断原发性恶性黑色素瘤的患者,随访至2015年。

主要发现

  • 高强度HRT使用与黑色素瘤风险的OR为1.21(95%CI 1.13-1.29),无剂量反应模式证据。
  • 近期高剂量使用者OR为1.28(95%CI 1.17-1.41),局部病变OR为1.25(95%CI 1.15-1.36),阴道内雌激素治疗OR为1.38(95%CI 1.13-1.68)。
  • 与未使用相比,诊断后新使用HRT与继发黑色素瘤无关联证据(完全调整HR 1.56,95%CI 0.64-3.80),持续使用HRT亦无关联(完全调整HR 1.26,95%CI 0.89-1.78)。
  • 全因死亡率观察到类似关联。

关键数值与推荐

  • HRT曾使用定义为1995年以来在索引日期前至少配发过一次HRT处方。
  • 使用条件逻辑回归计算OR,调整潜在混杂因素;队列分析使用Cox比例风险模型估计HR及95%CI。

临床怎么用

  • 研究结果提示HRT使用与黑色素瘤风险关联可能为非因果,可能与医疗利用增加和黑色素瘤检测增多有关。
  • HRT使用与黑色素瘤生存结局无关联,对有黑色素瘤病史患者使用HRT提供一定 reassurance。

局限性

  • 缺乏某些重要混杂因素信息,包括日光暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is hormone replacement therapy (HRT) associated with an increased risk of melanoma skin cancer or prognostic outcomes amongst post-menopausal women? SUMMARY ANSWER: Whilst we found evidence of an association with melanoma risk, the lack of dose-response and associations observed with recent use, localised disease and intravaginal oestrogens suggests this is a non-causal association. WHAT IS KNOWN ALREADY: Evidence on HRT and melanoma risk remains inconclusive, with studies providing conflicting results. Furthermore, evidence on melanoma survival is sparse, with only one previous study reporting protective associations with HRT use, likely attributable to immortal time bias. STUDY DESIGN, SIZE, DURATION: We conducted a nation-wide population-based case-control study and a retrospective cohort study utilising the Danish healthcare registries. Case-control analyses included 8279 women aged 45-85 with a first-ever diagnosis of malignant melanoma between 2000 and 2015, matched by age and calendar time to 165 580 population controls. A cohort of 6575 patients with a diagnosis of primary malignant melanoma between 2000 and 2013 and followed through 2015 was examined to determine if HRT use had an impact on melanoma survival outcomes. PARTICIPANTS/MATERIALS, SETTING, METHODS: Based on prescriptions dispensed since 1995, ever-use of HRT was defined as having filled at least one prescription for HRT prior to the index date. In total, 2629 cases (31.8%) and 47 026 controls (28.4%) used HRT. Conditional logistic regression was used to calculate odds ratios (ORs) for melanoma risk according to HRT use, compared with non-use, adjusting for potential confounders. For cohort analyses, Cox proportional hazards models was used to estimate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for second melanoma incidence and all-cause mortality associated with HRT. MAIN RESULTS AND THE ROLE OF CHANCE: High use of HRT was associated with an OR of 1.21 (95% CI 1.13-1.29) for melanoma risk, with no evidence of a dose-response pattern. Results were most pronounced amongst recent high users (OR, 1.28; 95% CI 1.17-1.41), for localised disease (OR, 1.25; 95% CI 1.15-1.36) and for intravaginal oestrogen therapy (OR, 1.38; 95% CI 1.13-1.68). Compared with non-use, there was no evidence of an association for secondary melanoma for post-diagnostic new-use (fully adjusted HR, 1.56; 95% CI 0.64-3.80) or continuous HRT use (fully adjusted HR, 1.26; 95% CI 0.89-1.78). Similar associations were observed for all-cause mortality. LIMITATIONS, REASONS FOR CAUTION: Despite the large sample size and the use of robust population-based registries with almost complete coverage, we lacked information on some important confounders including sun exposure. WIDER IMPLICATIONS OF THE FINDINGS: Whilst we cannot rule out an association between HRT use and melanoma risk, the associations observed are also compatible with increased healthcare utilisation and thus increased melanoma detection amongst HRT users. No association between HRT use and melanoma survival outcomes was observed. This should provide some reassurance to patients and clinicians, particularly concerning the use of HRT in patients with a history of melanoma. STUDY FUNDING/COMPETING INTEREST(S): B.M.H. is funded by a Cancer Research UK Population Research Postdoctoral Fellowship. The funding source had no influence on the design or conduct of this study. A.P. reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Servier, Novo Nordisk and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this article. The other authors have no competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Hicks BM, Kristensen KB, Pedersen SA, et al. Hormone replacement therapy and the risk of melanoma in post-menopausal women. Hum Reprod. 2019. PMID: 31803923. doi:10.1093/humrep/dez222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。